Clinical Trial

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.
Protocol Amendment History 1 change
notable Enrollment increased: 430 -> 480 participants 2026-05-14
Trial Details
NCT Number NCT07038343
Lead Sponsor Avenzo Therapeutics, Inc.
Conditions Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers
Enrollment 480 participants
Start Date 2025-06-04
Primary Completion 2030-06 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-13